Tagged with ALS

Turkey Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment.   Throughout many of the healthcare systems in North America and Europe, there is an increasing emphasis on outpatient and preventative care. In terms of health economics, governments see a great benefit in…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

USA 59 novel drugs were approved in the USA in 2018, representing a leap from the 46 approved in 2017 and 22 approved in 2016. 19 of the 59 drugs (32 percent) have been designated ‘first-in-class’ and 34 of the 59 drugs (58 percent) were approved to treat rare or “orphan”…

Korea An outline of the geographical distribution of clinical trial sites in South Korea. 184 medical institutions were designated by the Korean government as qualified clinical trial sites in December 2016, 57 of which were in the capital, Seoul.   Within Asia-Pacific, South Korea was the nation with the highest number…

Canada In total there were 27 new active substances (NASs) approved in Canada in 2018, 18 prescription pharmaceutical drugs and 9 biologics. In terms of companies that saw particular success last year, Merck (MSD outside of the US and Canada) had three prescription drugs approved, as did Swiss-headquartered Vifor Pharma. Global…

Spain Within the past decade, Spain has developed into a top player in the European clinical trial network. The pharmaceutical industry has been increasing its investment commitment in the market and taking advantage of the country’s outstanding public health system. These activities are being well received by the government, so much…

Spain Dr Juan Abarca Cidón, president of HM Hospitales, one of Spain’s leading private health groups, gives insight into the private health sector of the country, its relation to the public system, and the opportunities that exist to interact. Dr Abarca goes on to discuss the R&D capabilities of the group…

Spain Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he touches on the innovation ecosystem in Spain and how 3P works with clients, rather than for them, to achieve long-term…

Korea Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of partnerships and collaborations between different stakeholders in Korea as a key factor in making it such a strategic destination for both…

Turkey Yelda Ulu Colin, general manager of GE Healthcare in Turkey, offers her insider take on the country’s city hospitals project, highlighting the strengths of the Turkish PPP model and ultimately offering her view on the state of the Turkish medical devices industry as a whole.   Turkey is an important…

China Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) will bring to the drug development and clinical research landscape in China, the pressures and opportunities local companies…

Korea Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals how Daiichi Sankyo Korea plans to embrace the company’s global strategy of expanding into the new area of oncology.  …